Back to Research Home
NATRNatures Sunshine Products Inc
Health Care · Biotechnology: Pharmaceutical Preparations · Micro
$12.15−2.10%
As of 23 Oct 2026Mkt cap $249M
Stage 13
AVOID
Fundamentals
50.4/75
Technical
4.8/15
Independent
55.2/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −5.9%
- 3M
- −41.0%
- 6M
- −55.5%
- 1Y
- −15.0%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 12.0xHist median 20.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 12.4x
- FCF yield
- 8.1%
Quality
- ROIC
- 19.2%
- Operating margin
- 4.4%
- FCF margin
- 6.0%
- Current ratio
- 2.3x
Growth
- Revenue growth
- +5.7%Latest FY YoY
- Revenue CAGR
- +2.0%
- EPS CAGR
- −7.0%
- FCF CAGR
- +0.8%
Capital
- Share-count trend
- −2.6%3Y annualised
- Net cash
- $75M-2.1x OCF
Annual trend
- CAGR 2021–2025
- +2.0%
- Latest · 2025
- $0B
- YoY
- +5.7%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded